Equities Analysts Offer Predictions for VIR Q1 Earnings

Vir Biotechnology, Inc. (NASDAQ:VIR) – HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Vir Biotechnology in a note issued to investors on Friday, February 28th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of ($0.80) for the quarter. HC Wainwright has a “Buy” rating and a $110.00 price objective on the stock. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.92) per share. HC Wainwright also issued estimates for Vir Biotechnology’s Q2 2026 earnings at ($0.80) EPS, Q3 2026 earnings at ($0.81) EPS and Q4 2026 earnings at ($0.77) EPS.

A number of other equities research analysts have also recently commented on the company. JPMorgan Chase & Co. raised their price target on Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a report on Thursday, January 9th. Morgan Stanley raised Vir Biotechnology from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $10.00 to $20.00 in a report on Thursday, January 9th. Barclays lifted their target price on Vir Biotechnology from $26.00 to $31.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. Leerink Partners lifted their target price on Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 target price on shares of Vir Biotechnology in a report on Thursday, February 27th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.67.

Vir Biotechnology Stock Up 3.5 %

NASDAQ:VIR opened at $8.20 on Monday. The business’s 50-day simple moving average is $9.48 and its two-hundred day simple moving average is $8.49. The stock has a market cap of $1.13 billion, a PE ratio of -2.09 and a beta of 0.64. Vir Biotechnology has a 52 week low of $6.56 and a 52 week high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.09. The business had revenue of $12.37 million for the quarter, compared to analysts’ expectations of $8.14 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Vir Biotechnology by 29.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 181,325 shares of the company’s stock valued at $1,331,000 after buying an additional 40,954 shares during the period. Woodline Partners LP purchased a new stake in shares of Vir Biotechnology in the fourth quarter valued at approximately $991,000. Two Sigma Advisers LP boosted its holdings in shares of Vir Biotechnology by 74.8% in the fourth quarter. Two Sigma Advisers LP now owns 74,800 shares of the company’s stock valued at $549,000 after purchasing an additional 32,000 shares during the period. Stonepine Capital Management LLC purchased a new stake in shares of Vir Biotechnology in the fourth quarter valued at approximately $1,205,000. Finally, Sphera Funds Management LTD. boosted its holdings in shares of Vir Biotechnology by 523.4% in the fourth quarter. Sphera Funds Management LTD. now owns 581,829 shares of the company’s stock valued at $4,271,000 after purchasing an additional 488,500 shares during the period. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Insider Buying and Selling

In related news, Director George A. Scangos sold 10,964 shares of Vir Biotechnology stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total value of $107,556.84. Following the completion of the transaction, the director now owns 708,295 shares in the company, valued at approximately $6,948,373.95. This trade represents a 1.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Verneuil Vanina De sold 7,373 shares of the business’s stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $9.14, for a total value of $67,389.22. Following the transaction, the executive vice president now owns 79,460 shares of the company’s stock, valued at $726,264.40. This trade represents a 8.49 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,859 shares of company stock worth $326,458. Corporate insiders own 15.60% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).